Anticancer Effect of Radix Astragali on Cholangiocarcinoma *In Vitro* and Its Mechanism via Network Pharmacology

Yixiu Wang*
Bingzi Dong*
Weijie Xue
Yujie Feng
Chenyu Yang
Peng Liu
Jingyu Cao
Chengzhan Zhu

* Yixiu Wang and Bingzi Dong contributed equally to this work

Corresponding Authors: Chengzhan Zhu, e-mail: zhuchengz@qduhospital.cn, Jingyu Cao, e-mail: cjy7027@163.com

Source of support: This work was supported by the National Natural Science Foundation of China (No.81600490 and 81600691), the China Postdoctoral Science Foundation (No. 2016M602098 and 2018M640615), the Taishan Scholars Program of Shandong Province (No. 2019010668), and the Qingdao Postdoctoral Science Foundation (No. 2016046)

Background: This study used network pharmacology method and cell model to assess the effects of Radix Astragali (RA) on cholangiocarcinoma (CCA) and to predict core targets and molecular mechanisms.

Material/Methods: We performed an *in vitro* study to assess the effect of RA on CCA using CCK8 assay, the Live-Cell Analysis System, and trypan blue staining. The components and targets of RA were analyzed using the Traditional Chinese Medicine Systems Pharmacology database, and genes associated with CCA were retrieved from the GeneCards and OMIM platforms. Protein–protein interactions were analyzed with the STRING platform. The components–targets–disease network was built by Cytoscape. The TIMER database revealed the expression of core targets with diverse immune infiltration levels. GO and KEGG analyses were performed to identify molecular-biology processes and signaling pathways. The predictions were verified by Western blotting.

Results: Concentration-dependent antitumor activity was confirmed in the cholangiocarcinoma QBC939 cell line treated with RA. RA contained 16 active compounds, with quercetin and kaempferol as the core compounds. The most important biotargets for RA in CCA were caspase 3, MAPK8, MYC, EGFR, and PARP. The TIMER database revealed that the expression of caspase3 and MYC was related with diverse immune infiltration levels of CCA. The results of Western blotting showed RA significantly influenced the expression of the 5 targets that network pharmacology predicted.

Conclusions: RA is an active medicinal material that can be developed into a safe and effective multi-targeted anticancer treatment for CCA.

MeSH Keywords: Cholangiocarcinoma • Medicine, Chinese Traditional • Pharmacologic Actions

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/921162
**Background**

Cholangiocarcinoma (CCA) is the second most common hepatic malignant tumor, and its incidence has been increasing globally [1,2]. Most patients are in advanced stage. Treatments for patients who have unresectable or advanced CCA are limited. Various chemotherapeutic drugs have been used for treating CCA patients, like 5-fluorouracil, gemcitabine (GEM), cisplatin (CIS), and doxorubicin (DOX) [3], but CCA responds poorly to these drugs [4]. The current median overall survival after standard chemotherapy regimens is less than 1 year [5]. Therefore, it is necessary to develop alternative treatment approaches for CCA.

Humans have used herbs for treating disease for at least 60 000 years [6], showing they have a wide range of pharmacological properties, including anticancer activity [7–9]. Herbal formulae can act on many targets through their various components and play an integral role in key biological processes to exert therapeutic roles during disease development [10]. RA is a traditional Chinese medicine which was listed as being in the top grade in Shennong’s Materia Medica [11]. Several studies have shown that RA has antitumor activity [12]. RA extracts can inhibit the growth of lung adenocarcinoma cells [13]. Zhang et al. found that concentration-dependent antitumor activity was confirmed in laryngeal carcinoma SCC15 cell line treated with total RA glucosides [14], and RA can effectively promote oral cancer Hep-2 cell line apoptosis [15]. In addition, RA has immune-modulating activities [16]. It was reported that RA can inhibit the phagocytic activity of peritoneal macrophages, promote the transformation of spleen lymphocytes [17], secrete interleukin (IL)-2, and affect the activity of natural killer (NK) cells [17–19]. However, there is no published study that analyzed the effect of RA in treating CCA. Therefore, we performed the present study to assess the effect of RA on CCA and to identify its biological target and molecular mechanism to provide a scientific reference for further research.

Network pharmacology is an emerging and novel approach for exploring the systemic mechanisms of therapeutic compounds in disease [20,21]. The use of network pharmacology to identify herbal targets and potential mechanisms is becoming important to save money, effort, and time needed for drug discovery and design [22,23]. Network pharmacology has successfully realized the construction and visualization of drug–disease–target networks, which is helpful to evaluate the mechanism of drugs from multiple perspectives [24,25]. Network pharmacology can be applied in identifying the pharmacological targets and mechanisms of RA in CCA.

Therefore, we investigated the antitumor activity of RA on CCA in an in vitro study. We then used network pharmacology to analyze the core targets and biological functions, pathways, and mechanisms of RA in treating CCA. We verified the core targets and pathway by Western blotting. A schematic flowchart of the experiment design is shown in Figure 1.

**Material and Methods**

**Preparation of freeze-dried RA water extract**

Radix Astragali (root pieces, origin: Inner Mongolia, China) was purchased from Weifang Hospital of Traditional Chinese Medicine. We prepared aqueous extracts of freeze-dried RA. A total of 15 g of freeze-dried RA pieces was boiled in 500 mL water for 30 min. The water extract solution was concentrated to a volume of 250 mL. Finally, the extract solution was filtered with a 0.22-μm filter to remove bacteria and then was maintained at 4°C until use.

**Cell lines and cell culture**

The CCA cell line QBC939 cells were purchased from the Shanghai Cell Bank of the Chinese Science Academy (Shanghai, China). Cells were cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum in a cell culture incubator (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C and 5% CO₂.

**Cell viability assay**

QBC939 cells (5×10³ cells/well) were plated into 96-well plates and treated with various concentrations of RA (0, 100, 200, and 400 μg/mL), and PBS was used in the control group. After 24 h, cell viability was assessed by CCK8 assay. We cultured the cells for 1 h with CCK8 agent, then the optical density (OD) was measured at 450 nm on an enzyme-labeling instrument. Additionally, QBC939 cells were seeded into 6-well plates and cultured until the cell density reached 50%. After treatment with various concentrations of RA (0, 100, 200, and 400 μg/mL), the cells were imaged using an IncuCyte® S3 Live-Cell Analysis System (Essen BioScience) every 1 h, and 9 fields of view were imaged per well.

**Trypan blue staining**

After being treated with various concentrations of RA (0, 100, 200, and 400 μg/mL), QBC939 cells were digested and 50-μL cell suspension was mixed with 50 μL trypan blue staining solution. The mixture was placed into a hematocytometer and counted under a microscope within 10 min.
Collection chemical components and targets for RA

To evaluate the pharmacokinetics properties of RA, we used the TCMSP database (http://lsp.nwu.edu.cn/) [26] to collect information on chemical components for RA, which is a systems pharmacology resource used to evaluate traditional Chinese medicines or related compounds. With the pharmacokinetic information retrieval filter based on the TCMSP platform, the oral bioavailability (OB) and drug-likeness (DL) were set to ≥30% and ≥0.18 to obtain qualified herbal compounds. The chemical structures of the compounds were drawn using ChemBioOffice 2010.

Collection of disease targets

Potential genes associated with CCA were collected from GeneCards (https://www.genecards.org/) [27] with the keyword “cholangiocarcinoma” and Online Mendelian Inheritance in Man (OMIM) (https://www.omim.org/) [28] with the keyword “bile duct carcinoma”.

Construction of components–targets–disease network

Venny2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/) [29] was used to screen for common RA targets and CCA-related targets. Cytoscape-v3.7.1 [30] software was used to create the model of the target–disease and component–target network, and the Merge function was used to construct the component–target–disease network model. Results were further analyzed to determine the mutual relationships in the network model.

Protein–protein interaction (PPI) data

The Search Tool for the Retrieval of Interacting Genes (STRING) database (https://string-db.org/, ver.10.5) [31] was used to analyze protein–protein interactions of the common targets from the RA targets and CCA-related targets. The database defines PPIs with confidence ranges for data scores; in the present study, PPIs with medium confidence (0.4) were further examined.

Gene function and pathway enrichment analysis

clusterProfiler [32] is an R package for comparing biological themes among gene clusters, which can be used to analyze functional and pathway enrichment information on the gene of interest. The common targets were input into the R 3.6.0 platform by clusterProfiler software, using an enrichment analysis method with the Gene Ontology (GO) [33] and Kyoto Encyclopedia of Genes and Genomes (KEGG) [34] databases. Enriched GO terms were defined and relevant pathways with p values <0.05 were selected. Target–pathway and
constituent–pathway networks were built to show an overview of the interactions between RA targets and CCA [35].

Analysis of gene expression and tumor-infiltrating immune cells

Using the online tool TIMER (https://cistrome.shinyapps.io/timer/) [36], we investigated the correlation between the expression of core targets and tumor-infiltrating immune cells (B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells) in CCA, which is a comprehensive resource for systematic analysis of immune infiltrates across diverse cancer types [37].

Western blotting analysis

Total protein was extracted from QBC939 cells after RA treatment (0, 100, 200, and 400 μg/mL) and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by transfer of the proteins onto a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). The primary antibodies were: caspase3 (NO.9662; Cell Signaling Technology), SAPK/JNK (NO.9252; Cell Signaling Technology), p-SAPK/JNK (NO.4668; Cell Signaling Technology), c-MYC (NO.9402; Cell Signaling Technology), EGFR (NO.4267; Cell Signaling Technology), p-EGFR (NO.3777; Cell Signaling Technology), and PARP (NO.9542; Cell Signaling Technology).

Statistical analysis

Statistical analysis was performed using the SPSS program (version 23.0). All the data are presented as means±standard deviation. Differences were evaluated by Student’s t test, with p<0.05 considered statistically significant.

Results

RA inhibits the cell proliferation of QBC939 cells

After incubating the cells with various concentrations of RA (0, 100, 200, and 400 μg/mL) for 24 h, it was found that all tested concentrations of RA inhibited the proliferation of QBC939 cells with the CCK8 assay (p<0.05). Compared with the control group, growth inhibition increased in a concentration-dependent manner (100, 200, 400 μg/mL) (Figure 2A). The IncuCyte® S3 Live-Cell Analysis System was used to image surviving cells, which clearly revealed the gradual decrease in the numbers of QBC939 cells with increasing concentration (Figure 2B). RA also influenced the morphological characteristics and adherence of the cells to the plate; the cells displayed apoptotic morphology (Supplementary Figure 1).

Trypan blue counting analysis

Trypan blue staining is often applied to detect cell death. As shown in Figure 3, the living cells are non-stained, while dead cells are dyed blue. After counting the dead cells and living cells, we calculated the cell viability. The results showed that compared with the control group, the cell viability significantly decreased in a concentration-dependent manner after treatment with RA (p<0.05).

Screening results of components and target proteins

Using the TCMSP database, 20 herbal compounds were identified, 16 of which had corresponding targets. The 97 targets of the 16 compounds were obtained and the details are presented in Table 1. These 97 identified targets were further investigated.
Results of CCA targets

We acquired 1452 known correlated targets from GeneCards, and 83 known related targets were acquired from OMIM. After redundant names were deleted, 1529 known CCA-related targets were collected, and the list of targeted genes is shown in Supplementary Table 1.

Network construction

Of the 1529 known cholangiocarcinoma-related targets, 50 targets are involved in RA, and through Venny 2.1.0, the common targets were obtained, including PGR, PTGS1, CHEK1, PRSS1, CHRM3, ESR1, PPARG, GSK3B, F7, BCL2, CASP3, MAPK8, CYP1A1, SELE, ALOX5, GSTP1, AHR, NR1I3, GSTM1, EGFR, VEGFA, CCND1, CASP9, PLAU, RB1, IL6, TP63, ELK1, CASP8, RAF1, PRKCA, HIF1A, ERBB2, MYC, PTGER3, BIRC5, NOS3, HSPB1, CCNB1, NFE2L2.

Figure 3. The effect of RA on QBC939 cells detected by trypan blue staining assay. (A–D) Represents 0, 100, 200, 400 μg/mL, respectively. (E) Shows histogram analysis. Values represent means±SD, n=3, * P<0.05, ** P<0.01, *** P<0.001 compared with 0 μg/mL group.
## Table 1. Potential active compounds in HMM.

| Molecule ID   | Molecule name                                           | OB (%) | DL  | Chemical structure                                                                 |
|---------------|---------------------------------------------------------|--------|-----|-----------------------------------------------------------------------------------|
| MOL000211     | Mairin                                                 | 55.38  | 0.78| ![Chemical structure for Mairin](image)                                          |
| MOL000239     | Jaranol                                                | 50.83  | 0.29| ![Chemical structure for Jaranol](image)                                         |
| MOL000296     | Hederagenin                                            | 36.91  | 0.75| ![Chemical structure for Hederagenin](image)                                     |
| MOL000033     | (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a] phenanthen-3-ol | 36.23  | 0.78| ![Chemical structure for (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a] phenanthen-3-ol](image) |
| MOL000354     | Isorhamnetin                                           | 49.6   | 0.31| ![Chemical structure for Isorhamnetin](image)                                    |
| MOL000371     | 3,9-di-O-methylnissolin                                | 53.74  | 0.48| ![Chemical structure for 3,9-di-O-methylnissolin](image)                          |
| MOL000378     | 7-O-methylisomucronulatol                              | 74.69  | 0.3 | ![Chemical structure for 7-O-methylisomucronulatol](image)                       |
Table 1 continued. Potential active compounds in HMM.

| Molecule ID | Molecule name                                      | OB (%) | DL   | Chemical structure |
|-------------|----------------------------------------------------|--------|------|--------------------|
| MOL000379   | 9,10-dimethoxypterocarpan-3-O-β-D-glucoside       | 36.74  | 0.92 | ![Chemical structure](image1) |
| MOL000380   | (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofuran[3,2-c] chromen-3-ol | 64.26  | 0.42 | ![Chemical structure](image2) |
| MOL000387   | Bifendate                                         | 31.1   | 0.67 | ![Chemical structure](image3) |
| MOL000392   | Formononetin                                      | 69.67  | 0.21 | ![Chemical structure](image4) |
| MOL000417   | Calycosin                                         | 47.75  | 0.24 | ![Chemical structure](image5) |
| MOL000422   | Kaempferol                                        | 41.88  | 0.24 | ![Chemical structure](image6) |
| MOL000433   | FA                                                | 68.96  | 0.71 | ![Chemical structure](image7) |
NQO1, PARP1, CHEK2, HSF1, CRP, RASSF1, IRF1, ERBB3, PON1, and HK2, which all act on the pathway of treating cholangiocarcinoma by RA (Figure 4A, Table 2).

The 50 green nodes represent the target of cholangiocarcinoma, and the 15 pink nodes represent the target protein of the RA compounds. Network construction of compound disease targets consists of 67 nodes and 172 edges. Among them, 65 nodes and 107 edges directly reflect the interaction between the RA targets and cholangiocarcinoma targets (Figure 4B).

### PPI network of common targets

Protein–protein interactions (PPI) of the 50 disease-related targets were analyzed using the PPI network. After setting the interaction score to medium confidence and hiding disconnected nodes in the network, the PPI network contained 48 nodes and 361 edges (Figure 5A), with a 14.4 average node degree and PPI enrichment p value < 1.0e-16, showing the multi-target characteristics of RA. According to the degree of nodes exported from the STRING database, the order of key targets was analyzed, and the top 30 nodes with a degree ≥ 10 were selected (Figure 5B).

### GO and KEGG pathway analysis

GO and KEGG analyses were performed to further study the biological process of the 50 common targets. As shown in Figure 6A, the top 10 significantly enriched GO terms (adjusted p value < 0.001) were used and included the response to ubiquitin-like protein ligase binding, DNA-binding transcription activator activity, RNA polymerase II-specific, nuclear receptor activity, transcription factor activity, direct ligand regulated sequence-specific DNA binding, proximal promoter sequence-specific DNA binding, ubiquitin protein ligase binding, protein heterodimerization activity, RNA polymerase II proximal promoter sequence-specific DNA binding, Hsp90 protein binding, and E-box binding. The results were highly correlated with anticancer activities, demonstrating that RA exerted its effects against CCA by engaging in the above biological processes and cell functions.

Furthermore, these 50 genes participated in 79 KEGG pathways with adjusted p values < 0.01; after sorting the adjusted p values, the top 20 were analyzed (Figure 6B).

### Association of core targets’ expression with CCA purity and immune infiltration

The tumor microenvironment includes cancer cells, matrix cells, and infiltrating immune cells. Infiltrating immune cells are an independent predictor of sentinel lymph node status and survival of cancer patients [38,39]. Tumor purity plays a role in analyzing immune infiltration in clinical tumor samples by genomics methods [40]. The expressions of caspase3 and MYC were significantly negatively correlated with tumor purity via TIMER platform, while EGFR and PARP were not associated with tumor purity. Interestingly, we found expression of caspase3 was positively correlated with infiltration level of B cells in CCA, and expression of MYC was positively correlated with the infiltration level of B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells in CCA (Figure 7A, 7B).
Figure 4. Network construction of compound disease targets. (A) Venn diagram shows common part between RA with cholangiocarcinoma (CCA). (B) Network of RA compound targets and CCA targets. Note: drug compound1 represents (3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R,5S)-5-propan-2-yloctan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol); compound2 represents (6aR,11aR)-9,10-dimethoxy-6a,11a-dihydro-6H-benzofuranol[3,2-c]chromen-3-ol.
Table 2. Common targets between HMM and cholangiocarcinoma.

| Gene ID | Gene symbol | Gene name                                      |
|--------|-------------|------------------------------------------------|
| 5241   | PGR         | Progesterone receptor                          |
| 5742   | PTGS1       | Prostaglandin G/H synthase 1                   |
| 1111   | CHEK1       | Serine/threonine-protein kinase Chk1           |
| 5644   | PRSS1       | Trypsin-1                                      |
| 1131   | CHRM3       | Muscarinic acetylcholine receptor M3           |
| 2099   | ESR1        | Estrogen receptor                              |
| 5468   | PPARG       | Peroxisome proliferator activated receptor gamma|
| 2932   | GSK3B       | Glycogen synthase kinase-3 beta               |
| 2155   | F7          | Coagulation factor VII                         |
| 596    | BCL2        | Apoptosis regulator Bcl-2                     |
| 2932   | CASP3       | Caspase-3                                      |
| 2950   | GSTP1       | Glutathione S-transferase P                   |
| 196    | AHR         | Aryl hydrocarbon receptor                      |
| 9970   | NR1I3       | Nuclear receptor subfamily 1 group I member 3  |
| 2944   | GSTM1       | Glutathione S-transferase Mu 1                |
| 1956   | EGFR        | Epidermal growth factor receptor              |
| 7422   | VEGFA       | Vascular endothelial growth factor A          |
| 595    | CCND1       | G1/S-specific cyclin-D1                       |
| 842    | CASP9       | Caspase-9                                      |
| 5328   | PLAU        | Urokinase-type plasminogen activator          |
| 5925   | RB1         | Retinoblastoma-associated protein             |
| 3569   | IL6         | Interleukin-6                                  |
| 8626   | TP63        | Cellular tumor antigen p53                    |
| 2002   | Elk1        | ETS domain-containing protein Elk-1           |
| 841    | CASP8       | Caspase-8                                      |
| 5894   | RAF1        | RAF proto-oncogene serine/threonine-protein kinase|
| 5578   | PRKCA       | Protein kinase C alpha type                   |
| 3091   | HIF1A       | Hypoxia-inducible factor 1-alpha              |
| 2064   | ERBB2       | Receptor tyrosine-protein kinase erbB-2        |
| 4609   | MYC         | MYC proto-oncogene protein                    |
| 5733   | PTGER3      | Prostaglandin E2 receptor EP3 subtype         |
Table 2 continued. Common targets between HMM and cholangiocarcinoma.

| Gene ID | Gene symbol | Gene name                                           |
|---------|-------------|-----------------------------------------------------|
| 332     | BIRC5       | Baculoviral IAP repeat-containing protein 5          |
| 4846    | NOS3        | Nitric oxide synthase, endothelial                  |
| 3315    | HSPB1       | Heat shock protein beta-1                           |
| 891     | CCNB1       | G2/mitotic-specific cyclin-B1                       |
| 4780    | NFE2L2      | Nuclear factor erythroid 2-related factor 2          |
| 1728    | NQO1        | NAD(P)H dehydrogenase [quinone] 1                   |
| 142     | PARP1       | Poly [ADP-ribose] polymerase 1                      |
| 11200   | CHEK2       | Serine/threonine-protein kinase Chk2                |
| 3297    | HSF1        | Heat shock factor protein 1                          |
| 1401    | CRP         | C-reactive protein                                  |
| 11186   | RASSF1      | Ras association domain-containing protein 1          |
| 3659    | IRF1        | Interferon regulatory factor 1                       |
| 2065    | ERBB3       | Receptor tyrosine-protein kinase erbB-3              |
| 5444    | PON1        | Serum paraoxonase/arylesterase 1                     |
| 3099    | HK2         | Hexokinase-2                                        |

Changes in core target expression
To verify the core targets in the network of RA and CCA, we investigated the expression of core target proteins by Western blotting in QBC939 cells treated with RA, and found that RA downregulated the P-EGFR/EGFR and p-MAPK8/MAPK8 ratios, upregulated the cleaved caspase3/caspase3 ratio, and reduced the expression of c-MYC and PARP (Figure 8A, 8B). Western blotting results showed concentration-dependent antitumor activity in QBC939 cells treated with RA through these targets (p<0.05).

Discussion
Cholangiocarcinoma is a relatively common malignant tumor derived from the intrhepatic Due to difficulties in detection and drug resistance, it is very important to explore the regulation of CCA biological characteristics and find new treatment methods for multi-modal management of CCA.

Network pharmacology can improve drug efficacy and the success rate of clinical trials, as well as decrease in the costs of drug discovery via exploring the regulation of signaling pathways with multiple channels [42]. In our study, the network pharmacology findings from web-based databases revealed core gene targets, and we explored the biological functions, pathways, and mechanisms of RA in CCA. These findings support that RA is a promising resource with specific therapeutc effects on CCA.

RA is a type of astragalus, and several studies have shown that astragalus is associated with antitumor [12] and immune-modulating activities [16]. In network pharmacology analysis, the network of compound disease targets revealed quercetin and kaempferol as key active ingredients in RA responsible for the therapeutic effects against CCA. Several studies have suggested that quercetin is helpful for treating CCA as a dietary phytochemical with anti-inflammatory and antitumor effects [43,44] and may be useful against CCA as a cancer chemopreventive drug. Kaempferol has antioxidant, anti-inflammatory, and antitumor activities [45–47]. Qin et al. [48] showed that kaempferol has potent effects against CCA both in vitro and in vivo via the PI3K/AKT pathway, which is involved in apoptosis, proliferation, and invasion. In our in vitro study, the RA extract was cytotoxic and inhibited the proliferation of the bile duct carcinoma cell line QBC939.

Important predictive biotargets for RA in CCA were identified as caspase3, MAPK8, MYC, EGFR, and PARP. Caspase3, a cysteine-aspartic acid protease, plays a central role in the execution phase of cell apoptosis. As an executioner caspase, the caspase3 zymogen has activity after it is cleaved by an initiator caspase when apoptotic signaling events have occurred [49].
Figure 5. PPI network of common targets. (A) Nodes mean targets and colors of edges mean different relationships. (B) Top 30 nodes are likely key proteins in the interaction of cholangiocarcinoma.
Figure 6. GO and pathway analysis. (A) GO analysis of common targets of RA and cholangiocarcinoma. The Y-axis represents significant GO biological function processes and the X-axis represents the counts of enriched targets. The gradient of color represents the different adjusted p values. (B) KEGG analysis for common targets of RA and cholangiocarcinoma. The Y-axis represents significant KEGG pathways and the X-axis represents the ratio of enriched targets in a pathway to all common targets. The size of the nodes shows count of targets, and gradient of color represents the adjusted p value.
**Figure 7.** Correlation of core target expression with immune infiltration level in CCA. (A) Caspase3 expression level is significantly negatively related to tumor purity and positively related to the infiltration level of B cells in CCA. (B) MYC expression level is significantly negatively related to tumor purity and positively related to the infiltration level of B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells in CCA.

**Figure 8.** (A, B) Changes in core target proteins in QBC939 cells after RA treatment. GADPH was used as loading control. n=3, *p<0.05 compared with 0 µg/mL group.
Caspase3 plays a dominant role in the hallmark caspase cascade, which is characteristic of the apoptotic pathway triggered by extrinsic activation [50]. MAPK8, a transduction protein, controls several cellular processes, including cell proliferation and survival [51]. Nishikawa et al. reported that MAPK signaling appears to induce a biliary proliferation program in hepatocytes or liver bipotential cells, implicating this pathway in human CCA [52]. In human intrahepatic CCA, TNF is highly expressed near intrahepatic CCA lesions, and CCA p-JNK, and reactive oxygen species (ROS) accumulation in surrounding hepatocytes are present, causing cholangiocellular proliferation/differentiation and carcinogenesis. Targeting the ROS/TNF/JNK axis may improve intrahepatic CCA therapy [53].

C-MYC is the most well-known and studied member of the MYC oncoprotein family and it is estimated that in up to 70% of human cancers, c-MYC expression is elevated or deregulated through different mechanisms and is associated with an invasive cancer phenotype [54]. Many studies have demonstrated that c-MYC induction promotes cholestatic liver injury and CCA progression [55]. EGFR belongs to the HER/ErbB family of tyrosine kinase receptors. In many types of cancer, EGFR activation inhibits cell–cell adhesion by destabilizing the complex of E-cadherin/β-catenin, promotes tumor metastasis, and contributes to the procurement of a motile phenotype [56–58]. In CCA, overexpression of EGFR is related to tumor progression [59–64], and the EGFR/EGFR axis contributes to epithelial-mesenchymal transition in CCA tumor cells, promoting the progression of this type of cancer [65]. PARP is a nuclear DNA-binding protein and is an important component involved in single-strand break damage repair [66]. Upon DNA damage, PARP-1 catalyzes the PARylation of acceptor proteins and repairs damaged DNA via base excision repair to maintain genomic stability [67]. PARP inhibitors can theoretically enhance tumor cell death, and combining PARP inhibitors such as olaparib with radiation may contribute to treatment of CCA [68].

To further explore the biological functions of the core targets, we used TIMER database. The expression of caspase3 and MYC was negatively associated with tumor purity, which is correlated with diverse immune infiltration levels in CCA. Caspase3 expression levels are positively associated with the infiltration level of B cells in CCA, and the MYC expression level is positively associated with the infiltration level of B cells, CD4+ cells, macrophages, neutrophils, and dendritic cells in CCA. The results of TIMER suggest that the functions of core targets are related to immunological regulation of the tumor microenvironment. Immune infiltration is an emerging hallmark of cancer and plays an important role in tumor initiation and progression [69,70]. The tumor microenvironment is a key determinant in distant metastasis and development, in which evolution of the tumor can be traced back to immune-escaping clones [71]. Based on the relationship between the core genes and immune infiltration, RA may inhibit tumor initiation and progression by regulating the tumor microenvironment.

The KEGG results showed that RA regulates the EGFR tyrosine kinase inhibitor resistance pathway as the pharmacological mechanisms of the therapeutic effect of RA against CCA. An EGFR inhibitor was the first targeted drug used for tumor therapy and has been approved for treating metastatic non-small-cell lung cancer, pancreatic cancer, colorectal cancer, and squamous cell carcinoma of the head and neck [72]. As EGFR expression is decreased, downstream signaling in malignant tumor cells is inhibited, leading to inhibition of metastasis, growth, proliferation, differentiation, and angiogenesis and increased cancer cell apoptosis [73]. However, nearly all tumors acquire EGFR tyrosine kinase inhibitor resistance after various periods of time [74].

In our study, the Western blotting results showed that RA downregulated the P-EGFR/EGFR and p-MAPK8/MAPK8 ratios, upregulated the cleaved caspase3/caspase3 ratio, and reduced the expression of c-MYC and PARP. These in vitro results support the network pharmacology data and demonstrate that RA affects protein expression of core genes and alters the EGFR tyrosine kinase inhibitor resistance pathway. RA inhibits CCA progression by promoting cell apoptosis and blocking cell proliferation/differentiation and carcinogenesis.

**Conclusions**

RA appears to be an effective drug when used as adjuvant therapy. The core targets identified included caspase3, MAPK8, MYC, EGFR, and PARP in the network of RA and CCA, indicating potential as therapeutic biomolecules for treating CCA. Further studies are needed to demonstrate that RA is an active plant medicinal material useful for developing a safe and effective multi-targeted anticancer treatment for CCA.

**Conflict of interests**

None.
Supplementary Figure 1. The cells were imaged using the IncuCyte® S3 Live-Cell Analysis System. RA influenced the morphological characteristics and adherence of the cells to the plate.
**Supplementary Table 1. Targets from OMIM.**

| Gene/locus | Gene/locus name                                                                 | Gene/locus MIM number |
|------------|--------------------------------------------------------------------------------|-----------------------|
| BCC1       | Basal cell carcinoma, susceptibility to, 1                                     | 605462                |
| MYCL       | Oncogene MYC, lung carcinoma-derived                                           | 164850                |
| LMYC       | Oncogene MYC, lung carcinoma-derived                                           | 164850                |
| BCAS2      | Breast carcinoma amplified sequence 2                                          | 605783                |
| DAM1       | Breast carcinoma amplified sequence 2                                          | 605783                |
| PRN1       | Papillary thyroid carcinoma with papillary renal neoplasia                    | 605642                |
| PTCPRN     | Papillary thyroid carcinoma with papillary renal neoplasia                    | 605642                |
| RCCP1      | Papillary renal cell carcinoma, translocation-associated                       | 179755                |
| PRCC       | Papillary renal cell carcinoma, translocation-associated                       | 179755                |
| BCC2       | Basal cell carcinoma, susceptibility to, 2                                     | 613058                |
| NMTC3      | Nonmedullary thyroid carcinoma 3                                              | 606240                |
| ABCB11     | ATP-binding cassette, subfamily B, member 11 (bile salt export pump)           | 603201                |
| BSEP       | ATP-binding cassette, subfamily B, member 11 (bile salt export pump)           | 603201                |
| SPGR       | ATP-binding cassette, subfamily B, member 11 (bile salt export pump)           | 603201                |
| PFIC2      | ATP-binding cassette, subfamily B, member 11 (bile salt export pump)           | 603201                |
| SLC10A6    | Solute carrier family 10 (sodium/bile acid cotransporter family), member 6     | 611366                |
| SOAT       | Solute carrier family 10 (sodium/bile acid cotransporter family), member 6     | 611366                |
| SLC10A7    | Solute carrier family 10 (sodium/bile acid cotransporter family), member 7     | 611459                |
| SSASK5     | Solute carrier family 10 (sodium/bile acid cotransporter family), member 7     | 611459                |
| BCC3       | Basal cell carcinoma, susceptibility to, 3                                     | 613059                |
| NPCA2      | Nasopharyngeal carcinoma susceptibility to, 2                                  | 161550                |
| BCC6       | Basal cell carcinoma, susceptibility to, 6                                     | 613063                |
| AKR1D1     | Bile acid synthesis defect, congenital, 2                                      | 604741                |
| SRD5B1     | Bile acid synthesis defect, congenital, 2                                      | 604741                |
| Gene/locus | Gene/locus name                                                                 | Gene/locus MIM number |
|-----------|---------------------------------------------------------------------------------|-----------------------|
| CBAS2     | Bile acid synthesis defect, congenital, 2                                        | 604741                |
| NCRNA00197| Papillary thyroid carcinoma susceptibility candidate 1 gene                       | 617440                |
| PTCSC1    | Papillary thyroid carcinoma susceptibility candidate 1 gene                       | 617440                |
| BCCS      | Basal cell carcinoma, susceptibility to, 5                                        | 613062                |
| BAAT      | Bile acid coenzyme A: amino acid N-acyltransferase (glycine N-choloyltransferase) | 602938                |
| CEL       | Carboxyl-ester lipase (bile-salt stimulated lipase)                               | 114840                |
| BSSL      | Carboxyl-ester lipase (bile-salt stimulated lipase)                               | 114840                |
| CELL      | Carboxyl-ester lipase (bile-salt stimulated lipase)                               | 114840                |
| MODY8     | Carboxyl-ester lipase (bile-salt stimulated lipase)                               | 114840                |
| SART1     | Squamous cell carcinoma antigen recognized by T cells 1                           | 605941                |
| HOMS1     | Squamous cell carcinoma antigen recognized by T cells 1                           | 605941                |
| ANC       | Anal canal carcinoma                                                              | 105580                |
| BCC4      | Basal cell carcinoma, susceptibility to, 4                                        | 613061                |
| AQP2      | Aquaporin-2 (collecting duct)                                                    | 107777                |
| SART3     | Squamous cell carcinoma antigen recognized by T cells 3                           | 611684                |
| P100      | Squamous cell carcinoma antigen recognized by T cells 3                           | 611684                |
| KIAA0156  | Squamous cell carcinoma antigen recognized by T cells 3                           | 611684                |
| TIP110    | Squamous cell carcinoma antigen recognized by T cells 3                           | 611684                |
| SLC10A2   | Solute carrier family 10 (sodium/bile acid cotransporter family), member 2        | 601295                |
| NTCP2     | Solute carrier family 10 (sodium/bile acid cotransporter family), member 2        | 601295                |
| PBAM      | Solute carrier family 10 (sodium/bile acid cotransporter family), member 2        | 601295                |
| SLC10A1   | Solute carrier family 10 (sodium/bile acid cotransporter family), member 1        | 182396                |
| NTCP1     | Solute carrier family 10 (sodium/bile acid cotransporter family), member 1        | 182396                |
| HDMCP     | Hepatocellular carcinoma-downregulated mitochondrial carrier protein              | 609911                |
| C14orf68  | Hepatocellular carcinoma-downregulated mitochondrial carrier protein              | 609911                |
| HCCAT5    | Hepatocellular carcinoma-associated transcript 5                                   | 615613                |
| HTA       | Hepatocellular carcinoma-associated transcript 5                                   | 615613                |
| MSPC      | Palmoplantar carcinoma, multiple self-healing                                     | 616964                |
| ICT1      | Immature colon carcinoma transcript 1                                             | 603000                |
| DS1       | Immature colon carcinoma transcript 1                                             | 603000                |
| DCC       | Deleted in colorectal carcinoma                                                   | 120470                |
| MRMV1     | Deleted in colorectal carcinoma                                                   | 120470                |
| HGPPS2    | Deleted in colorectal carcinoma                                                   | 120470                |
| SERPINB4  | Serpin peptidase inhibitor, clade B (ovalbumin), member 4 (squamous cell carcinoma antigen 2) | 600518                |
| SCCA2     | Serpin peptidase inhibitor, clade B (ovalbumin), member 4 (squamous cell carcinoma antigen 2) | 600518                |
| Gene/locus          | Gene/locus name                                                                 | Gene/locus MIM number |
|---------------------|---------------------------------------------------------------------------------|-----------------------|
| SERPINB3            | Serpin peptidase inhibitor, clade B (ovalbumin), member 3 (squamous cell        | 600517                |
|                     | carcinoma antigen 1)                                                            |                       |
| SCCA1               | Serpin peptidase inhibitor, clade B (ovalbumin), member 3 (squamous cell        | 600517                |
|                     | carcinoma antigen 1)                                                            |                       |
| TCO                 | Thyroid carcinoma, nonmedullary, with cell oxyphilia                            | 603386                |
| BCAS4               | Breast carcinoma amplified sequence 4                                           | 607471                |
| BCAS1               | Breast carcinoma amplified sequence                                             | 602968                |
| NABC1               | Breast carcinoma amplified sequence                                             | 602968                |
| PICSAR              | p38-inhibited cutaneous squamous cell carcinoma-associated long intergenic      | 617191                |
|                     | noncoding RNA                                                                   |                       |
| LINCO0162           | p38-inhibited cutaneous squamous cell carcinoma-associated long intergenic      | 617191                |
|                     | noncoding RNA                                                                   |                       |
| NL1C                | p38-inhibited cutaneous squamous cell carcinoma-associated long intergenic      | 617191                |
|                     | noncoding RNA                                                                   |                       |
| SLC10A3             | Solute carrier family 10 (sodium/bile acid cotransporter family) member 3      | 312090                |
|                     | (protein p3)                                                                    |                       |
| P3                  | Solute carrier family 10 (sodium/bile acid cotransporter family) member 3      | 312090                |
|                     | (protein p3)                                                                    |                       |

References:

1. Khan SA, Taylor-Robinson SD, Toledano MB et al: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol, 2002; 36(2): 806–13
2. Saha SK, Zhu AX, Fuchs CS, Brooks GA: Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist, 2016; 21(5): 594–99
3. Khan SA, Davidson BR, Goldin RD et al: Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut, 2012; 61(12): 1657–69
4. Iwashashi S, Ishibashi H, Utsunomiya T et al: Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines. J Med Invest, 2011; 58(1–2): 106–9
5. Valle J, Wasan H, Palmer DH et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010; 362(14): 1273–81
6. Fabricant DS, Farnsworth NR: The value of plants used in traditional medicine for drug discovery. Environ Health Perspect, 2001; 109(Suppl. 1): 69–75
7. Kuttan G, Menon LG, Antony S, Kuttan R: Anticarcinogenic and antimetastatic activity of Iscador. Anticancer Drugs, 1997; 8(Suppl. 1): S15–16
8. Kwon SB, Kim MJ, Yang JM et al: Evaluation of the anticancer effect of Astragalus polybotrys extract on lung adenocarcinoma cells. Pract Clin J Integr Tradit Chin West Med, 2011; 4–5 [in Chinese]
9. Song Y, Bai WL: [Effect of astragalus on cell proliferation and apoptosis in laryngeal carcinoma cell line.] Pract Pharm Clin Remed, 2013; 16: 5–7 [in Chinese]
10. Yang Z, Zhu S, Liu S et al: Anticancer effect of Astragalus polybotrys on pancreatic cancer and cholangiocarcinoma cell lines. Chin Med, 2011; 58(1–2): 106–9
11. Valve J, Wasan H, Palmer DH et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010; 362(14): 1273–81
12. Fabricant DS, Farnsworth NR: The value of plants used in traditional medicine for drug discovery. Environ Health Perspect, 2001; 109(Suppl. 1): 69–75
13. Kuttan G, Menon LG, Antony S, Kuttan R: Anticarcinogenic and antimetastatic activity of Iscador. Anticancer Drugs, 1997; 8(Suppl. 1): S15–16
14. Song Y, Bai WL: [Effect of Astragalus on cell proliferation and apoptosis in laryngeal carcinoma cell line.] Pract Pharm Clin Remed, 2013; 16: 5–7 [in Chinese]
15. Zhang Z: [Effect of total glucosides of Astragalus on the viability of SCC15 oral cancer cells and its mechanism.] Chin Pract Med, 2013; 8: 249–50 [in Chinese]
16. Li R, Chen W, Wang W et al: Extraction, characterization of Astragalus polysaccharides and its immune modulating activities in rats with gastric cancer. Carbohydrate Polymers, 2009; 78(4): 738–42
17. Xu YH, Zhu Y: [The effect of Huangqi injection on immune function in rats with scald.] Chin Tradit Patent Med, 2000; 22: 494–96 [in Chinese]
18. Jin H: Immunomodulatory effects of Astragalus membranaceus and Astragalus polysaccharides from IL-2. Chin J Immunol, 1989: 308–10 [in Chinese]
19. XianBo WU, QuanYu DU, Liang YL, Ping MA: Effects of Astragalus polysaccharide on immune function of lung-qi deficiency model mice. China Pharmacy, 2012; 23(47): 4417–18
20. Li R, Ma X, Song Y et al: Anti-colorectal cancer targets of resveratrol and biological molecular mechanism: Analyses of network pharmacology, human and experimental data. J Cell Biochem, 2019 [Epub ahead of print]
21. Su M, Guo C, Liu M et al: Therapeutic targets of vitamin C on liver injury and associated biological mechanisms: A study of network pharmacology. Int Immunopharmacol, 2019; 66: 383–87
22. Bi YH, Zhang LH, Chen SJ, Ling QZ: Antitumor mechanisms of curcumae rhizoma based on network pharmacology. Evid Based Complement Alternat Med, 2018; 2018: 4509892
23. Hu Y, Chen D: Analysis of the action mechanism of Fang Ji Huang Qi decoction in treating rheumatoid arthritis by network pharmacology. Evid Based Complement Alternat Med, 2018; 2018: 4509892
27. Steiger G, Rosen N, Plaschkes I et al: The GeneCards Suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics, 2016; 54: 1.3.0.1–1.30.33

28. Amberger JS, Hamosh A: Searching Online Mendelian Inheritance in Man (OMIM): A knowledgebase of human genes and genetic phenotypes. Curr Protoc Bioinformatics, 2017; 58: 1.2.1–1.2.12

29. Oliveros JC: Venn. An interactive tool for comparing lists with Venn diagrams. https://bioinformatics.ncl.ac.uk/venn/index.html

30. Shannon P, Markiel A, Ozier O et al: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res, 2003, 13(11): 2498–504

31. Szklarczyk D, Morris HR, Cook H et al: The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res, 2017; 45(D1): D33–61

32. Yu G, Wang LG, Han Y, He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5): 284–87

33. The Gene Ontology Consortium: Expansion of the Gene Ontology knowledgeedge and resources. Nucleic Acids Res, 2017; 45(D1): D331–38

34. Kanehisa M, Goto S: KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res, 2000; 28(1): 27–30

35. Kanehisa M, Furumichi M, Tanabe M et al: KEGG: New perspectives on genome, pathways, diseases and drugs. Nucleic Acids Res, 2017, 45(D1): D353–61

36. Li B, Severson E, Pignon JC et al: Comprehensive analyses of tumor immunology: Implications for cancer immunotherapy. Genome Biol, 2016; 17(1): 174

37. Li T, Fan J, Wang B et al: TIMER: A web server for comprehensive analyses of tumor-infiltrating immune cells. Cancer Med, 2017; 7(21): e108–10

38. Ohtani H: Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun, 2007; 7: 4

39. Azimi F, Scolyer RA, Rumcheva P et al: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol, 2012; 30(21): 2678–83

40. Yoshikawa K, Shohmarogidol M, Martinez E et al: Infiltrating tumour purity and stromal and immune cell admixture from expression data. Nat Commun, 2013; 4: 2612

41. Hoyos S, Navas MC, Restrepo JC, Botero RC: Current controversies in cholangiocarcinoma. World J Gastroenterol, 2009; 15(36): 4511–17

42. Zhang GB, Li QY, Chen QL, Su SB: Network pharmacology: A new approach to drug discovery and development. Trends Pharmacol Sci, 2008; 29(6): 685–93

43. Brito AF, Ribeiro M, Abrantes AM et al: New approach for treatment of primary liver tumors: The role of quercetin. Nutr Cancer, 2016; 68(2): 250–66

44. Li T, Wang LG, Han Y, He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012, 16(5): 284–87

45. Cui Y, Morgenstern H, Greenland S et al: Dietary flavonoid intake and lung health and cancer chemoprevention. Food Chem, 2013; 138(4): 2099–107

46. Qin Y, Cui W, Yang X, Tong B: Kaempferol inhibits the growth and metastasis of cholangiocarcinoma in vitro and in vivo. Acta Biochim Biophys Sin, 2016; 48(2): 238–45

47. Nishikawa Y, Sone M, Nagahama Y et al: Tumor necrosis factor-alpha promotes bile ductular transdifferentiation of mature hepatocytes in vitro. J Cell Biochem, 2013; 114(4): 831–43

48. Zhang GB, Li QY, Chen QL, Su SB: Network pharmacology: A new approach to drug discovery and development. Trends Pharmacol Sci, 2008; 29(6): 685–93

49. Walters J, Pop C, Scott FL et al: A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis. Biochem J, 2009; 424(3): 335–45

50. Perry DK, Smyth MJ, Stennerke HR et al: Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem, 1997; 272(30): 18530–33

51. Roskoski R Jr: EKR1/2 MAP kinases: Structure, function, and regulation. Pharmacol Res, 2012; 66(2): 105–43

52. Nishikawa Y, Sone M, Nagahama Y et al: Tumor necrosis factor-alpha promotes bile ductular transdifferentiation of mature hepatocytes in vitro. J Cell Biochem, 2013; 114(4): 831–43

53. Yuan D, Huang S, Berger E et al: Kupffer cell-derived Tnf triggers cholangio- cellular tumorigenesis through Jnk due to chronic mitochondrial dysfunction and ROS. Cancer Cell, 2017; 31(6): 771–89.e776

54. Dang Chi V: Nyc on the path to cancer. Cell, 2012; 149(1): 22–35

55. Zhang GB, Li QY, Chen QL, Su SB: Network pharmacology: A new approach to drug discovery and development. Trends Pharmacol Sci, 2008; 29(6): 685–93

56. Cui Y, Morgenstern H, Greenland S et al: Dietary flavonoid intake and lung health and cancer chemoprevention. Food Chem, 2013; 138(4): 2099–107